GSK plc announced the marketing authorisation of Exdensur (depemokimab) by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA). In the UK, Exdensur is now approved in two indications: ...

Dec 17 () - Insmed said on Wednesday it had discontinued the development of its ​experimental anti-inflammatory drug to treat a ‌chronic sinus condition after it failed to show benefit in ‌a mid-stage ...

The latest announcement is out from Insmed ( (INSM) ).

Insmed stock crumbled late Wednesday after the highly rated biotech company scrapped one of its brensocatib studies.

Insmed Incorporated (Nasdaq:INSM), a people-first global biopharmaceutical company striving to deliver first- and ...

The U.S. health regulator has approved GSK's add-on treatment for severe asthma, offering a less frequently dosed option, but ...

Drug trials offer people with cancer hope and free medicine, but they also create incentives for doctors in private clinics ...

Insmed Inc (NASDAQ:INSM) stock tumbled 17.2% in after-hours trading Wednesday after the biopharmaceutical company announced its Phase 2b BiRCh study of brensocatib in patients with chronic ...

Regulators in the UK and US are the first to approve GSK's Exdensur, a long-acting, twice-yearly IL-5 inhibitor for severe ...

GSK's asthma drug Exdensur, the first biologic for twice-yearly dosing, gains FDA approval for severe asthma treatment.

The London-based pharmaceuticals firm explained the approval for Exdensur is as an add-on maintenance treatment of severe asthma "characterised by an eosinophilic phenotype" in both adult and ...

The FDA has approved Exdensur depemokimab-ulaa as an add-on maintenance therapy for severe asthma in patients aged 12 and older, supported by Phase III SWIFT trial data showing significant reductions ...